Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.

Pal SK, Forero-Torres A, Thompson JA, Morris JC, Chhabra S, Hoimes CJ, Vogelzang NJ, Boyd T, Bergerot PG, Adashek JJ, Li H, Yu X, Gartner EM, Carret AS, Smith DC.

Cancer. 2019 Jan 9. doi: 10.1002/cncr.31912. [Epub ahead of print]

PMID:
30624766
2.

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.

Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, Claus R, Wermke M, Hariharan S, von Heydebreck A, Kasturi V, Chand V, Gulley JL.

J Immunother Cancer. 2018 Oct 22;6(1):111. doi: 10.1186/s40425-018-0424-9.

3.

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P.

Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9.

PMID:
30267200
4.

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.

PMID:
30232224
5.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

PMID:
30181416
6.

Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.

Kang KH, Grubb W, Sawlani K, Gibson MK, Hoimes CJ, Rogers LR, Lavertu P, Yao M.

Am J Otolaryngol. 2018 Sep - Oct;39(5):642-645. doi: 10.1016/j.amjoto.2018.06.003. Epub 2018 Jun 5. Review.

PMID:
29903623
7.

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK.

Br J Cancer. 2018 May;118(11):1434-1441. doi: 10.1038/s41416-018-0087-9. Epub 2018 May 16.

PMID:
29765151
8.

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P.

Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Review.

PMID:
29606341
9.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P.

Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.

PMID:
29517810
10.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.

PMID:
28982750
11.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.

JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.

12.

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C.

J Natl Compr Canc Netw. 2016 Oct;14(10):1213-1224.

13.

Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study.

Antunes J, Viswanath S, Rusu M, Valls L, Hoimes C, Avril N, Madabhushi A.

Transl Oncol. 2016 Apr;9(2):155-162. doi: 10.1016/j.tranon.2016.01.008.

14.

Editorial Comment.

Hoimes CJ, Madabhushi A.

Urology. 2016 Feb;88:132-3. doi: 10.1016/j.urology.2015.09.043. No abstract available.

PMID:
26964790
15.

Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort.

Kiechle JE, Abouassaly R, Gross CP, Dong S, Cherullo EE, Zhu H, Trinh QD, Sun M, Meropol NJ, Hoimes CJ, Ialacci S, Kim SP.

Urology. 2016 Apr;90:69-74. doi: 10.1016/j.urology.2015.10.035. Epub 2015 Dec 24.

PMID:
26724412
16.

Characteristics and Survival of Malignant Cardiac Tumors: A 40-Year Analysis of >500 Patients.

Oliveira GH, Al-Kindi SG, Hoimes C, Park SJ.

Circulation. 2015 Dec 22;132(25):2395-402. doi: 10.1161/CIRCULATIONAHA.115.016418. Epub 2015 Oct 14.

PMID:
26467256
17.

Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.

Peiris PM, Abramowski A, Mcginnity J, Doolittle E, Toy R, Gopalakrishnan R, Shah S, Bauer L, Ghaghada KB, Hoimes C, Brady-Kalnay SM, Basilion JP, Griswold MA, Karathanasis E.

Cancer Res. 2015 Apr 1;75(7):1356-65. doi: 10.1158/0008-5472.CAN-14-1540. Epub 2015 Jan 27.

18.

Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.

Valls L, Hoimes C, Sher A, Hu L, Lee Z, Muzic R, Avril N.

Semin Roentgenol. 2014 Jul;49(3):238-41. doi: 10.1053/j.ro.2014.09.001. Epub 2014 Sep 16. No abstract available.

PMID:
25497908
19.

Targeted nanotechnology for cancer imaging.

Toy R, Bauer L, Hoimes C, Ghaghada KB, Karathanasis E.

Adv Drug Deliv Rev. 2014 Sep 30;76:79-97. doi: 10.1016/j.addr.2014.08.002. Epub 2014 Aug 9. Review.

20.

The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles.

Deng Y, Saucier-Sawyer JK, Hoimes CJ, Zhang J, Seo YE, Andrejecsk JW, Saltzman WM.

Biomaterials. 2014 Aug;35(24):6595-602. doi: 10.1016/j.biomaterials.2014.04.038. Epub 2014 May 9.

21.

Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.

Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM.

Nanomedicine. 2013 Nov;9(8):1124-34. doi: 10.1016/j.nano.2013.05.017. Epub 2013 Jun 11.

22.

Surface modified poly(β amino ester)-containing nanoparticles for plasmid DNA delivery.

Fields RJ, Cheng CJ, Quijano E, Weller C, Kristofik N, Duong N, Hoimes C, Egan ME, Saltzman WM.

J Control Release. 2012 Nov 28;164(1):41-8. doi: 10.1016/j.jconrel.2012.09.020. Epub 2012 Oct 5.

23.

Redefining hormone resistance in prostate cancer.

Hoimes CJ, Kelly WK.

Ther Adv Med Oncol. 2010 Mar 1;2(2):107-123.

24.

Hodgkin's lymphoma of the breast.

Hoimes CJ, Selbst MK, Shafi NQ, Rose MG, Rosado MF.

J Clin Oncol. 2010 Jan 10;28(2):e11-3. doi: 10.1200/JCO.2009.23.1613. Epub 2009 Nov 2. No abstract available.

PMID:
19884545
26.

TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality.

Hoimes CJ, Kelly WK.

Update Cancer Ther. 2009;3(4):157-159. No abstract available.

28.

Therapeutic tools in pancreatic cancer.

Hoimes CJ, Strimpakos AS, Saif MW.

JOP. 2009 Mar 9;10(2):118-22.

29.

Pancreatic cancer: translating lessons from mouse models.

Strimpakos AS, Hoimes C, Saif MW.

JOP. 2009 Mar 9;10(2):98-103.

Supplemental Content

Loading ...
Support Center